Evaluation of optic neuritis following human papillomavirus vaccination

References

• Centers for Disease Control and Prevention. Incidence, prevalence, and cost of sexually transmitted infections in the United States. Atlanta, GA: Department of Health and Human Services, Centers for Disease Control and Prevention; 2013
   Google Scholar
• Parkin DM, Bray F. The burden of HPV-related cancers. Vaccine 2006; 24:S11-25; https://doi.org/10.1016/j.vaccine.2006.05.111
   Web of Science ®Google Scholar
• Watson M, Saraiya M, Wu X. Update of HPV-associated female genital cancers in the United States, 1999–2004. J Womens Health (Larchmt) 2009; 18:1731-8; PMID:19951205; https://doi.org/10.1089/jwh.2009.1570
   PubMed Web of Science ®Google Scholar
• Gillison ML. Human papillomavirus-related diseases: oropharynx cancers and potential implications for adolescent HPV vaccination. J Adolesc Health 2008; 43:S52-60; PMID:18809146; https://doi.org/10.1016/j.jadohealth.2008.07.002
   PubMed Web of Science ®Google Scholar
• Bosch FX, Burchell AN, Schiffman M, Giuliano AR, de Sanjose S, Bruni L, Tortolero-Luna G, Kjaer SK, Muñoz N. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 2008; 26:K1-16; PMID:18847553; https://doi.org/10.1016/j.vaccine.2008.05.064
   PubMed Web of Science ®Google Scholar
• FDA. Gardasil 9
   Google Scholar
• Markowitz LE, Dunne E, Saraiya M, Lawson H, Chesson H, Unger E. Quadrivalent human papillomavirus vaccine. MMWR Morb Mortal Wkly Rep 2007; 56:1-24; PMID:17218934
   PubMedGoogle Scholar
• FDA. Complete List of Vaccines Licensed for Immunization and Distribution in the US
   Google Scholar
• Centers for Disease Control and Prevention. FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report 2010; 59(20):626.
   PubMedGoogle Scholar
• Reisinger KS, Block SL, Lazcano-Ponce E, Samakoses R, Esser MT, Erick J, Puchalski D, Giacoletti KE, Sings HL, Lukac S. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: A randomized controlled trial. Pediatr Infect Dis J 2007; 26:201-9; PMID:17484215; https://doi.org/10.1097/01.inf.0000253970.29190.5a
   PubMed Web of Science ®Google Scholar
• Brown DR, Kjaer SK, Sigurdsson K, Iversen O-E, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Tay EH, Garcia P. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16–26 years. J Infect Dis 2009; 199:926-35; PMID:19236279; https://doi.org/10.1086/597307
   PubMed Web of Science ®Google Scholar
• Einstein MH, Baron M, Levin MJ, Chatterjee A, Edwards RP, Zepp F, Carletti I, Dessy FJ, Trofa AF, Schuind A. Comparison of the immunogenicity and safety of Cervarix™ and Gardasil® human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years. Hum Vaccin 2009; 5:705-19; PMID:19684472; https://doi.org/10.4161/hv.5.10.9518
   PubMed Web of Science ®Google Scholar
• Paavonen J, Naud P, Salmeron J, Wheeler C, Chow S, Apter D, Kitchener H, Castellsague X, Teixeira J, Skinner S. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): Final analysis of a double-blind, randomised study in young women. Lancet 2009; 374:301-14; https://doi.org/10.1016/S0140-6736(09)61248-4
   PubMed Web of Science ®Google Scholar
• FDA. Gardasil package insert
   Google Scholar
• FDA. Cervarix package insert
   Google Scholar
• Shoenfeld Y, Aron-Maor A. Vaccination and autoimmunity—‘vaccinosis’: A dangerous liaison? J Autoimmun 2000; 14:1-10; PMID:10648110; https://doi.org/10.1006/jaut.1999.0346
   PubMed Web of Science ®Google Scholar
• Siegrist C-A, Lewis EM, Eskola J, Evans SJ, Black SB. Human papilloma virus immunization in adolescent and young adults: a cohort study to illustrate what events might be mistaken for adverse reactions. Pediatr Infect Dis J 2007; 26:979-84; PMID:17984802; https://doi.org/10.1097/INF.0b013e318149dfea
   PubMed Web of Science ®Google Scholar
• Orbach H, Agmon-Levin N, Zandman-Goddard G. Vaccines and autoimmune diseases of the adult. Discov Med 2010; 9:90-7; PMID:20193633
   PubMed Web of Science ®Google Scholar
• Salemi S, D'Amelio R. Could autoimmunity be induced by vaccination? Int Rev Immunol 2010; 29:247-69; PMID:20521925; https://doi.org/10.3109/08830181003746304
   PubMed Web of Science ®Google Scholar
• Debeer P, De Munter P, Bruyninckx F, Devlieger R. Brachial plexus neuritis following HPV vaccination. Vaccine 2008; 26:4417-9; PMID:18602437; https://doi.org/10.1016/j.vaccine.2008.06.074
   PubMed Web of Science ®Google Scholar
• Borja-Hart NL, Benavides S, Christensen C. Human papillomavirus vaccine safety in pediatric patients: an evaluation of the vaccine adverse event reporting system. Ann Pharmacother 2009; 43:356-9; PMID:19155346; https://doi.org/10.1345/aph.1L492
   PubMed Web of Science ®Google Scholar
• Macartney KK, Chiu C, Georgousakis M, Brotherton JM. Safety of human papillomavirus vaccines: A review. Drug Saf 2013; 36:393-412; PMID:23637071; https://doi.org/10.1007/s40264-013-0039-5
   PubMed Web of Science ®Google Scholar
• Pellegrino P, Carnovale C, Pozzi M, Antoniazzi S, Perrone V, Salvati D, Gentili M, Brusadelli T, Clementi E, Radice S. On the relationship between human papilloma virus vaccine and autoimmune diseases. Autoimmun Rev 2014; 13:736-41; PMID:24468416; https://doi.org/10.1016/j.autrev.2014.01.054
   PubMed Web of Science ®Google Scholar
• Slade BA, Leidel L, Vellozzi C, Woo EJ, Hua W, Sutherland A, Izurieta HS, Ball R, Miller N, Braun MM. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA 2009; 302:750-7; PMID:19690307; https://doi.org/10.1001/jama.2009.1201
   PubMed Web of Science ®Google Scholar
• Gee J, Naleway A, Shui I, Baggs J, Yin R, Li R, Kulldorff M, Lewis E, Fireman B, Daley MF. Monitoring the safety of quadrivalent human papillomavirus vaccine: Findings from the vaccine safety datalink. Vaccine 2011; 29:8279-84; PMID:21907257; https://doi.org/10.1016/j.vaccine.2011.08.106
   PubMed Web of Science ®Google Scholar
• Slade BA, Gee J, Broder KR, Vellozzi C. Comment on the contribution by Souayah et al.,“Guillain–Barré syndrome after Gardasil vaccinati: Data from vaccine adverse event reporting system 2006–2009”. Vaccine 2011; 29:865-6; PMID:21111783; https://doi.org/10.1016/j.vaccine.2010.11.031
   PubMed Web of Science ®Google Scholar
• Sutton I, Lahoria R, Tan I, Clouston P, Barnett M. CNS demyelination and quadrivalent HPV vaccination. Mult Scler 2009; 15:116-9; PMID:18805844; https://doi.org/10.1177/1352458508096868
   PubMed Web of Science ®Google Scholar
• Verstraeten T, Descamps D, David M-P, Zahaf T, Hardt K, Izurieta P, Dubin G, Breuer T. Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. Vaccine 2008; 26:6630-8; PMID:18845199; https://doi.org/10.1016/j.vaccine.2008.09.049
   PubMed Web of Science ®Google Scholar
• Naleway AL, Gold R, Drew L, Riedlinger K, Henninger ML, Gee J. Reported adverse events in young women following quadrivalent human papillomavirus vaccination. J Womens Health (Larchmt) 2012; 21:425-32; PMID:22229713; https://doi.org/10.1089/jwh.2011.2895
   PubMed Web of Science ®Google Scholar
• Grimaldi-Bensouda L, Guillemot D, Godeau B, Bénichou J, Lebrun-Frenay C, Papeix C, Labauge P, Berquin P, Penfornis A, Benhamou PY. Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects. J Intern Med 2014; 275:398-408; PMID:24206418; https://doi.org/10.1111/joim.12155
   PubMed Web of Science ®Google Scholar
• Scheller NM, Svanström H, Pasternak B, Arnheim-Dahlström L, Sundström K, Fink K, Hviid A. Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system. JAMA 2015; 313:54-61; PMID:25562266; https://doi.org/10.1001/jama.2014.16946
   PubMed Web of Science ®Google Scholar
• Souayah N, Michas-Martin P, Nasar A, Krivitskaya N, Yacoub HA, Khan H, Qureshi AI. Guillain–Barré syndrome after Gardasil vaccination: data from vaccine adverse event reporting system 2006–2009. Vaccine 2011; 29:886-9; PMID:20869467; https://doi.org/10.1016/j.vaccine.2010.09.020
   PubMed Web of Science ®Google Scholar
• Chen RT, Glasser JW, Rhodes PH, Davis RL, Barlow WE, Thompson RS, Mullooly JP, Black SB, Shinefield HR, Vadheim CM. Vaccine safety datalink project: A new tool for improving vaccine safety monitoring in the United States. Pediatrics 1997; 99:765-73; PMID:9164767; https://doi.org/10.1542/peds.99.6.765
   PubMed Web of Science ®Google Scholar
• Izurieta HS, Zuber P, Bonhoeffer J, Chen RT, Sankohg O, Laserson KF, Sturkenboom M, Loucq C, Weibel D, Dodd C. Roadmap for the international collaborative epidemiologic monitoring of safety and effectiveness of new high priority vaccines. Vaccine 2013; 31:3623-7; PMID:23707171; https://doi.org/10.1016/j.vaccine.2013.05.027
   PubMed Web of Science ®Google Scholar
• Whitaker HJ, Paddy Farrington C, Spiessens B, Musonda P. Tutorial in biostatistics: The self-controlled case series method. Stat Med 2006; 25:1768-97; PMID:16220518; https://doi.org/10.1002/sim.2302
   PubMed Web of Science ®Google Scholar
• Kulldorff M. SaTScan user guide for version 9.0. 2011
   Google Scholar
• Baggs J, Gee J, Lewis E, Fowler G, Benson P, Lieu T, Naleway A, Klein NP, Baxter R, Belongia E. The vaccine safety datalink: A model for monitoring immunization safety. Pediatrics 2011; 127:S45-S53; PMID:21502240; https://doi.org/10.1542/peds.2010-1722H
   PubMed Web of Science ®Google Scholar